accession,name,description,Parent study,Study Disease/Focus,Study Design,Study Markerset,Study Molecular Data Type,Study Content,Ancestry (computed),NIH Institute,Study Consent,Release Date,Embargo Release Date,Related Terms
"phs003027.v1.p1","Rapid Acceleration of Diagnostics - TECH (RADx-TECH): Test US Bank Study","This biorepository is being established to obtain, store, and share body fluid samples for SARS-CoV-2 research. Samples will be obtained at the study sites. The overall study duration will be  , e.g., ED or inpatient units, ambulatory clinics, or COVID-19 community screening events. Note for data in RADx: Instructions for requesting individual","Not Applicable","COVID-19","Collection","Not Provided","Not Provided","","","OD","GRU --- General research use","2022-11-22","",""
"phs002682.v1.p1","Rapid Acceleration of Diagnostics - TECH (RADx-TECH): 2183 SARS-CoV-2    Rapid Antigen Test","There are two device studies under the 2183 banner. The 2183b study uses an enhanced visual display compared to the original study (2183a), so it has been renamed. These prospective   be included in the data files. Note for data in RADx: Instructions for requesting individual-level data are available on RADx Data Hub at https://radx","Not Applicable","COVID-19","Methods","Not Provided","Not Provided","","","OD","GRU --- General research use","2022-11-21","",""
"phs002739.v1.p1","Rapid Acceleration of Diagnostics - TECH (RADx-TECH): COVID-19 Test At    Home Feasibility Sub-Study","The purpose of this feasibility study is to gather knowledge that will inform a future larger study using at-home SARS-CoV-2 testing and digital tools. This study will: 1) Test the   that enrolled an observational cohort into an intervention only arm of future cluster RCT. Note for data in RADx: Instructions for requesting individual","Not Applicable","COVID-19","Methods","Not Provided","Not Provided","","","OD","GRU --- General research use","2022-11-22","",""
"phs003026.v1.p1","Rapid Acceleration of Diagnostics - TECH (RADx-TECH): COVID-19 Test At    Home Efficacy Sub-Study","The FDA has published a safety communication regarding At-Home COVID-19 Antigen Tests (https://www.fda.gov/medical-devices/safety-communications/home-covid-19-antigen-tests-take-steps-reduce-your-risk-false-negative-fda-safety-communication). In support of this notice, a preprint, Performance of Screening for SARS-CoV-2 using Rapid Antigen Tests to  -person (on day 1) and digitally (days 2-6). Note for data in RADx: Instructions for requesting individual-level data are available on RADx Data Hub at","Not Applicable","COVID-19","Prospective Longitudinal Cohort","Not Provided","Not Provided","","","OD","GRU --- General research use","2022-11-22","",""
"phs002737.v1.p1","Rapid Acceleration of Diagnostics - TECH (RADx-TECH): Accurate, Sensitive    and Affordable POC and At Home Testing Device","The purpose of this study is to test the performance of the Saliva Test device in detecting SARS CoV-2 in symptomatic people for Emergency Use Authorization (EUA) as a point-of-care   in RADx: Instructions for requesting individual-level data are available on RADx Data Hub at https://radx-hub.nih.gov/home. Apply for data access in","Not Applicable","COVID-19","Methods","Not Provided","Not Provided","","","OD","GRU --- General research use","2022-11-22","",""
"phs002738.v1.p1","Rapid Acceleration of Diagnostics - TECH (RADx-TECH): Ultra-Sensitive    Immunoassay Test for Quantitation of SARS-CoV-2 Antigen","The 5534 study prospective clinical study seeks to examine the performance of the 5534 device, for the detection of SARS-CoV-2 nucleocapsid protein antigen compared to the Roche 6800 Cobas PCR   collected nasal, saliva, and dried bloodspot specimens. Note: no device performance data will be included in the dataset. Note for data in RADx: Instructions","Not Applicable","COVID-19","Methods","Not Provided","Not Provided","","","OD","GRU --- General research use","2022-11-22","",""
"phs002736.v1.p1","Rapid Acceleration of Diagnostics - TECH (RADx-TECH): Rapid Manufacturing    Scale-up for Compact Point-of-Care EUA SARS-CoV-2 RT-PCR Test","This prospective clinical study seeks to examine the performance of the device, a sample-to-answer nucleic acid PCR amplification platform solution for the point-of-care (POC) detection of SARS-CoV-2, compared to the   data in RADx: Instructions for requesting individual-level data are available on RADx Data Hub at https://radx-hub.nih.gov/home. Apply for data access in","Not Applicable","COVID-19","Methods","Not Provided","Not Provided","","","OD","GRU --- General research use","2022-11-21","",""
"phs002871.v1.p1","Rapid Acceleration of Diagnostics - Underserved Populations (RADx-UP): A    Dynamic COVID-19 Community-Engaged Testing Strategy in Alabama (COVID    COMET AL)","This study seeks to understand the factors associated with COVID-19 morbidity and mortality disparities and to lay the foundation to reduce disparities for those underserved and vulnerable populations that are  -care PCR test developed via RADx-TECH, which had particular uptake in rural jails across Alabama. In accordance with DHHS reporting requirements, we","Not Applicable","COVID-19","Cross-Sectional","Not Provided","Not Provided","","","OD","GRU --- General research use","2022-12-02","",""
